Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
Castro-Villegas, Carmen; Pérez-Sánchez, Carlos; Escudero, Alejandro; Filipescu, Ileana; Verdu, Miriam; Ruiz-Limón, Patricia; Aguirre, Ma Angeles; Jiménez-Gomez, Yolanda; Font, Pilar; Rodriguez-Ariza, Antonio; Peinado, Juan Ramon; Collantes-Estévez, Eduardo; González-Conejero, Rocío; Martinez, Constantino; Barbarroja, Nuria; López-Pedrera, Chary.
Arthritis Res Ther
; 17: 49, 2015 Mar 09.
Artigo em Inglês | MEDLINE | ID: mdl-25860297
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.
Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.
Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis.
Circulating miR-10a as Predictor of Therapy Response in Rheumatoid Arthritis Patients Treated with Methotrexate.
The Micro-RNA Expression Profiles of Autoimmune Arthritis Reveal Novel Biomarkers of the Disease and Therapeutic Response.
An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability.
Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
[PRECLINICAL RHEUMATOID ARTHRITIS].